-
Mashup Score: 0Dr Kluger on the FDA Approval of Lifileucel in Advanced Melanoma - 2 month(s) ago
Harriet Kluger, MD, discusses the FDA approval of the tumor infiltrating lymphocyte therapy lifileucel for patients with advanced melanoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
In the treatment of unresectable or metastatic Merkel cell carcinoma, immune checkpoint inhibitors have activity and tolerability.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1What Accounts for Recent Reductions in Cutaneous Malignant Melanoma Mortality? | Cancer Nursing Today - 3 month(s) ago
While the overall incidence of cutaneous malignant melanoma rose annually from 1994-2006 and is expected to rise until 2029, survival has improved since 2010.
Source: cancernursingtoday.comCategories: General Medicine News, Partners & KOLsTweet-
📉 While the overall incidence of cutaneous malignant melanoma rose annually from 1994-2006, a new study published in @CancerEpid shows improved survival and reduced mortality since 2010. ➡️ Learn what may account for these improved outcomes: https://t.co/xzkxU4dLW6 #melsm https://t.co/ods53objNb
-
-
Mashup Score: 1
Results from a long-term analysis of the phase 3 IMCgp100-202 trial indicate that tebentafusp results in better disease control and long-lasting responses in those with HLA-A*02:01–positive, previously untreated metastatic uveal melanoma.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Oncolytic Adenovirus TILT-123 Combined With TIL Therapy Is Safe in Metastatic Melanoma - 4 month(s) ago
Intravenous and intratumoral treatment with TILT-123 was found to be safe and feasible, with no dose-limiting toxicities when given alone or in combination with tumor infiltrating lymphocyte therapy in patients with advanced, metastatic melanoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
mRNA-4157 is being evaluated in combination with pembrolizumab as part of the phase 2b KEYNOTE-942/mRNA-4157-P201 trial in patients with completely resected, high-risk, stage III to IV melanoma.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6SD-101 With Immune Checkpoint Inhibition Generates Positive Results in Uveal Melanoma Liver Metastasis - 4 month(s) ago
Treatment with SD-101 distributed via pressure-enabled drug delivery with immune checkpoint inhibition was tolerated and resulted in the depletion of Tregs, M-MDSCs, and M2 macrophages in liver metastases in patients with uveal melanoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Dr Nathan on the Design of the IMCgp100-202 Trial in Uveal Melanoma - 5 month(s) ago
Paul D. Nathan, MBBS, PhD, FRCP, discusses the design of the phase 3 IMCgp100-202 trial of tebentafusp-tebn in patients with previously untreated, HLA-A*02:01–positive metastatic uveal melanoma, highlighting the key enrollment criteria of the randomized, open-label study.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Omid Hamid, MD, director, Melanoma Program, The Angeles Clinic and Research Institute, Cedars-Sinai, discusses the rationale for a phase 1 trial of fianlimab plus cemiplimab in patients with advanced melanoma who have received prior adjuvant PD-1 inhibitors.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0AHN Cancer Institute Unveils State-of-the-Art Skin Cancer Center at West Penn Hospital - 6 month(s) ago
Allegheny Health Network Cancer Institute unveiled its new, state-of-the-art Skin Cancer Center at West Penn Hospital, featuring a first-in-the-region full-body 3D imaging system that provides custom digital surveillance for skin abnormalities.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
WATCH: Dr Kluger on the FDA Approval of Lifileucel in Advanced Melanoma @YaleCancer @us_fda #melsm https://t.co/yAkpDjHkOu